[A18-61] Encorafenib (melanoma) - Benefit assessment according to §35a Social Code Book V
Last updated 22.03.2019
Project no.:
A18-61
Commission:
Commission awarded on 27.09.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation
Added benefit not proven for pretreated or treatment-naive patients
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-17 | Encorafenib (melanoma) - Addendum to Commission A18-61 | Commission completed |
| A24-101 | Binimetinib and encorafenib (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission work started |
| A20-56 | Encorafenib (colorectal cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-03-22 A G-BA decision was published.